BISOPROLOL I KhRONIChESKAYa SERDEChNAYa NEDOSTATOChNOST'

Abstract

Therapy with β-adrenergic receptor blockers leads to a decrease in the risk of death and serious cardiovascular complications in patients with chronic heart failure (CHF). Treatment with β-blockers has a particular significant effect on the risk of fatal ventricular arrhythmias in patients with high risk of sudden death. Bisoprolol is metabolically neutral and has good bioavailability, long half-life, and balanced clearance. High efficacy and good tolerability allows to consider this drug as one of the main medicines recommended for use in patients with CHF.